Marijuana Research Today is a free monthly online journal that collates and summarizes the latest research about Marijuana, including details on benefits, cancer, effects, uses, addiction.

Volume 5 (2008), Issue 1 (January)

1. Influence of cannabis use on severity of hepatitis C disease.
   Clin Gastroenterol Hepatol, 6(1): 69-75. [Abstract] [Full-text]
2. Chronic Delta(9)-Tetrahydrocannabinol During Adolescence Provokes Sex-Dependent Changes in the Emotional Profile in Adult Rats: Behavioral and Biochemical Correlates.
   Neuropsychopharmacology. [Abstract] [Full-text]
3. Child and adolescent externalizing behavior and cannabis use disorders in early adulthood: an Australian prospective birth cohort study.
   Addict Behav, 33(3): 422-38. [Abstract] [Full-text]
4. Direct NMR analysis of cannabis water extracts and tinctures and semi-quantitative data on Delta(9)-THC and Delta(9)-THC-acid.
   Phytochemistry, 69(2): 562-70. [Abstract] [Full-text]
5. Evolutional pattern of drug use by medical students.
   Addict Behav, 33(3): 490-5. [Abstract] [Full-text]
6. The occurrence of cannabis use disorders and other cannabis-related problems among first-year college students.
   Addict Behav, 33(3): 397-411. [Abstract] [Full-text]
7. Self-efficacy, social support and service integration at medical cannabis facilities in the San Francisco Bay area of California.
   Health Soc Care Community, 16(1): 31-41. [Abstract] [Full-text]
8. Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo.
   Oncogene, 27(3): 339-46. [Abstract] [Full-text]
9. Blunted Psychotomimetic and Amnestic Effects of Delta-9-Tetrahydrocannabinol in Frequent Users of Cannabis.
   Neuropsychopharmacology. [Abstract] [Full-text]
10. Stereoselective total synthesis of (-)-perrottetinene and assignment of its absolute configuration.
    Org Lett, 10(2): 269-71. [Abstract] [Full-text]
11. Co-morbid substance misuse in psychiatric patients: prevalence and association with length of inpatient stay.
    J Psychopharmacol, 22(1): 92-9. [Abstract] [Full-text]
12. New technology and new initiatives in U.S. workplace testing.
    Forensic Sci Int, 174(2): 120-4. [Abstract] [Full-text]
13. The U.S. Mandatory Guidelines for Federal Workplace Drug Testing Programs: current status and future considerations.
    Forensic Sci Int, 174(2): 111-9. [Abstract] [Full-text]
14. Excretion of Delta9-tetrahydrocannabinol in sweat.
    Forensic Sci Int, 174(2): 173-7. [Abstract] [Full-text]
15. Driving under the influence in Greece: a 7-year survey (1998-2004).
    Forensic Sci Int, 174(2): 157-60. [Abstract] [Full-text]
16. Brain imaging study of the acute effects of Delta(9)-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana.
    Psychopharmacology (Berl), 196(1): 119-31. [Abstract] [Full-text]
17. Managing confidentiality in illicit drugs research: ethical and legal lessons from studies in remote Aboriginal communities.
    Intern Med J, 38(1): 60-3. [Abstract] [Full-text]
18. Bullous lung disease due to marijuana.
    Respirology, 13(1): 122-7. [Abstract] [Full-text]
19. Gender and non-medical use of prescription opioids: results from a national US survey.
    Addiction, 103(2): 258-68. [Abstract] [Full-text]
20. Atrial fibrillation and marijuana smoking.
    Int J Clin Pract, 62(2): 308-13. [Abstract] [Full-text]
21. The relation between childhood proactive and reactive aggression and substance use initiation.
    J Abnorm Child Psychol, 36(2): 261-71. [Abstract] [Full-text]
22. Local administration of a cannabinoid agonist alters norepinephrine efflux in the rat frontal cortex.
    Neurosci Lett, 431(1): 1-5. [Abstract] [Full-text]
23. The diverse CB(1) and CB(2) receptor pharmacology of three plant cannabinoids: Delta(9)-tetrahydrocannabinol, cannabidiol and Delta(9)-tetrahydrocannabivarin.
    Br J Pharmacol, 153(2): 199-215. [Abstract] [Full-text]
24. Direct suppression of autoreactive lymphocytes in the central nervous system via the CB(2) receptor.
    Br J Pharmacol, 153(2): 271-6. [Abstract] [Full-text]
25. Cannabinoid CB(2) receptors in the gastrointestinal tract: a regulatory system in states of inflammation.
    Br J Pharmacol, 153(2): 263-70. [Abstract] [Full-text]
26. Variations in coital and noncoital sexual repertoire among adolescent women.
    J Adolesc Health, 42(2): 170-6. [Abstract] [Full-text]
27. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample.
    Psychol Med. [Abstract] [Full-text]
28. CB(2) cannabinoid receptors: new vistas.
    Br J Pharmacol, 153(2): 177-8. [Abstract] [Full-text]
29. Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes.
    Brain Res, 1191: 1-11. [Abstract] [Full-text]
30. Metamemory in recreational ecstasy polydrug users: what do self-reports of memory failures mean?
    J Psychopharmacol. [Abstract] [Full-text]
31. Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient.
    J Psychopharmacol. [Abstract] [Full-text]
32. Cognitive performance in recreational ecstasy polydrug users: a two-year follow-up study.
    J Psychopharmacol. [Abstract] [Full-text]
33. Real-world memory and executive processes in cannabis users and non-users.
    J Psychopharmacol. [Abstract] [Full-text]
34. Individual, group and community risk and protective factors for alcohol and drug use among Swedish adolescents.
    Eur J Public Health, 18(1): 12-8. [Abstract] [Full-text]
35. Substance use in emergency medicine training programs.
    Acad Emerg Med, 15(1): 45-53. [Abstract] [Full-text]
36. Prenatal Marijuana Exposure and Intelligence Test Performance at Age 6.
    J Am Acad Child Adolesc Psychiatry. [Abstract] [Full-text]
37. Risky driving among young Australian drivers II: Co-occurrence with other problem behaviours.
    Accid Anal Prev, 40(1): 376-86. [Abstract] [Full-text]
38. Item response theory analysis of DSM-IV cannabis abuse and dependence criteria in adolescents.
    J Am Acad Child Adolesc Psychiatry, 47(2): 165-73. [Abstract] [Full-text]
39. Prospective assessment of cannabis withdrawal in adolescents with cannabis dependence: a pilot study.
    J Am Acad Child Adolesc Psychiatry, 47(2): 174-8. [Abstract] [Full-text]
40. Prenatal methamphetamine use and neonatal neurobehavioral outcome.
    Neurotoxicol Teratol, 30(1): 20-8. [Abstract] [Full-text]
41. Ecstasy use and higher-level cognitive functions: weak effects of ecstasy after control for potential confounds.
    Psychol Med. [Abstract] [Full-text]
42. Regulating compassion: an overview of Canada's federal medical cannabis policy and practice.
    Harm Reduct J, 5(1): 5. [Abstract] [Full-text]
43. Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use.
    Pharmacotherapy, 28(2): 156-69. [Abstract] [Full-text]
44. Waterpipe tobacco smoking: Knowledge, attitudes, beliefs, and behavior in two U.S. samples.
    Nicotine Tob Res, 10(2): 393-8. [Abstract] [Full-text]

© 2004-2008 Marijuana Research Today. All Rights Reserved.